Mitchell G Miglis, MD

Offices

3 locations · Stanford Health Care · 3,152 clinicians in this group

Looking this up.

Hospitals listed: Stanford Health Care. That is not proof they admit you there this week.

Plans that list them

5 plans · 2 carriers

A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Miglis’s office at (650) 723-4000 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.

5 of 5 plans

Sort by

Plans whose provider directory lists this clinician

SCAN Balance (HMO C-SNP)	SCAN Health Plan	Listed	Oct 3, 2026
SCAN Classic (HMO)	SCAN Health Plan	Listed	Oct 3, 2026
SCAN MyChoice (HMO)	SCAN Health Plan	Listed	Oct 3, 2026
SCAN Strive (HMO C-SNP)	SCAN Health Plan	Listed	Oct 3, 2026
DualConnect (HMO D-SNP)	Santa Clara Family Health Plan	Listed	Sep 1, 2026

California Medical Board record

Licence A121294 · Current

Licensed to practise in California · since 2012 · expires 2028-03-31 · University of Florida College of Medicine.

No disciplinary actions, convictions, malpractice judgments or citations in this record.

Hospitals they work in

1 hospital

These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.

Stanford Health CareStanford, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency departmentPart of Stanford Health Care, which runs 3 hospitalsHome of Stanford Cancer Institute, a National Cancer Institute designated comprehensive cancer centrePatients rate it 4 of 5 · 83% would definitely recommend it
Overall rating: 5 of 5 starsWorse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 5.31 (4.24 to 6.37) · 8,661 cases, Jul 2022 – Jun 2024Worse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 14.1 (12.7 to 15.7) · 2,191 cases, Jan 2024 – Dec 2024Better than the national rate — Postoperative respiratory failure rate: 4.08 (1.95 to 6.21) · 5,296 cases, Jul 2022 – Jun 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.317, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.446, Oct 2024 – Sep 2025Better than the national rate — SSI - Colon Surgery: 0.241, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.7 (0.6 to 0.9) · 3,348 cases, Jan 2024 – Dec 2024

See every measure and the patient survey for Stanford Health Care

Behind the star rating — Deaths: 5 better, 3 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 2 better, 5 the same, 4 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.

Sort by

Every scored measure at Stanford Health Care

Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths	5.31 (4.24 to 6.37) · 8,661 cases	Worse	Jul 2022 – Jun 2024
Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits	14.1 (12.7 to 15.7) · 2,191 cases	Worse	Jan 2024 – Dec 2024
Postoperative respiratory failure rateComplications and deaths	4.08 (1.95 to 6.21) · 5,296 cases	Better	Jul 2022 – Jun 2024
Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections	0.317	Better	Oct 2024 – Sep 2025
Clostridium Difficile (C.Diff)Infections	0.446	Better	Oct 2024 – Sep 2025
SSI - Colon SurgeryInfections	0.241	Better	Oct 2024 – Sep 2025
Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits	0.7 (0.6 to 0.9) · 3,348 cases	Better	Jan 2024 – Dec 2024
Abdominopelvic accidental puncture or laceration rateComplications and deaths	1.06 (0.45 to 1.67) · 5,374 cases	No different	Jul 2022 – Jun 2024
CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths	0.86 (0.72 to 1)	No different	Jul 2022 – Jun 2024
Death rate among surgical inpatients with serious treatable complicationsComplications and deaths	166.09 (137.88 to 194.3) · 470 cases	No different	Jul 2022 – Jun 2024
Death rate for CABG surgery patientsComplications and deaths	1.1 · 192 cases	None	Jul 2022 – Jun 2025
Death rate for COPD patientsComplications and deaths	6.4 · 146 cases	None	Jul 2022 – Jun 2025
Death rate for heart attack patientsComplications and deaths	9.7 · 253 cases	None	Jul 2022 – Jun 2025
Death rate for heart failure patientsComplications and deaths	6.3 · 880 cases	None	Jul 2022 – Jun 2025
Death rate for pneumonia patientsComplications and deaths	10.3 · 935 cases	None	Jul 2022 – Jun 2025
Death rate for stroke patientsComplications and deaths	8.7 · 501 cases	None	Jul 2023 – Jun 2025
Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths	2.1 · 7,730 cases	None	Jul 2024 – Jun 2025
Iatrogenic pneumothorax rateComplications and deaths	0.13 (0 to 0.27) · 20,799 cases	No different	Jul 2022 – Jun 2024
In-hospital fall-associated fracture rateComplications and deaths	0.28 (0.14 to 0.43) · 23,182 cases	No different	Jul 2022 – Jun 2024
Postoperative acute kidney injury requiring dialysis rateComplications and deaths	0.94 (0.2 to 1.68) · 5,694 cases	No different	Jul 2022 – Jun 2024
Postoperative hemorrhage or hematoma rateComplications and deaths	2.36 (1.54 to 3.19) · 7,846 cases	No different	Jul 2022 – Jun 2024
Postoperative sepsis rateComplications and deaths	5.2 (3.76 to 6.64) · 5,603 cases	No different	Jul 2022 – Jun 2024
Postoperative wound dehiscence rateComplications and deaths	1.38 (0.23 to 2.53) · 2,211 cases	No different	Jul 2022 – Jun 2024
Pressure ulcer rateComplications and deaths	0.52 (0.21 to 0.83) · 19,915 cases	No different	Jul 2022 – Jun 2024
Rate of complications for hip/knee replacement patientsComplications and deaths	3.6 · 416 cases	None	Apr 2023 – Mar 2025
Central Line Associated Bloodstream Infection (ICU + select Wards)Infections	0.869	No different	Oct 2024 – Sep 2025
MRSA BacteremiaInfections	0.857	No different	Oct 2024 – Sep 2025
SSI - Abdominal HysterectomyInfections	0.368	No different	Oct 2024 – Sep 2025
Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits	16.2 · 247 cases	None	Jul 2023 – Jun 2025
Heart failure (HF) 30-Day Readmission RateUnplanned return visits	20.5 · 1,021 cases	None	Jul 2023 – Jun 2025
Hospital return days for heart attack patientsUnplanned return visits	47.8 · 258 cases	None	Jul 2022 – Jun 2025
Hospital return days for heart failure patientsUnplanned return visits	-1.6 · 990 cases	None	Jul 2022 – Jun 2025
Hospital return days for pneumonia patientsUnplanned return visits	20.8 · 976 cases	None	Jul 2022 – Jun 2025
Pneumonia (PN) 30-Day Readmission RateUnplanned return visits	16.5 · 959 cases	None	Jul 2023 – Jun 2025
Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits	5.2 (4.4 to 6.2) · 2,191 cases	No different	Jan 2024 – Dec 2024
Rate of readmission after hip/knee replacementUnplanned return visits	5.1 · 425 cases	None	Jul 2023 – Jun 2025
Rate of readmission for CABGUnplanned return visits	9.6 · 158 cases	None	Jul 2023 – Jun 2025
Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits	19.6 · 183 cases	None	Jul 2023 – Jun 2025
Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits	12.7 (10.4 to 15.4) · 4,578 cases	No different	Jan 2022 – Dec 2024

What patients said (6,810 patients answered, 25% of those asked)

Sort by

Patient survey stars by topic at Stanford Health Care

Cleanliness	4
Nurse communication	4
Doctor communication	4
Communication about medicines	3
Discharge information	4
Overall hospital rating	4
Quietness	2
Recommend hospital	5

Sort by

Share of patients giving the best answer at Stanford Health Care

Room was "always" clean	75%
Nurses "always" communicated well	82%
Doctors "always" communicated well	81%
Staff "always" explained	63%
Yes, staff "did" give patients this information	89%
Yes, staff "did" give patients information about help after discharge	89%
Doctors "always" explained things so they could understand	76%
Doctors "always" listened carefully	80%
Doctors "always" treated them with courtesy and respect	87%
Patients who gave a rating of "9" or "10" (high)	79%
Staff "always" explained new medications	76%
Nurses "always" explained things so they could understand	77%
Nurses "always" listened carefully	79%
Nurses "always" treated them with courtesy and respect	88%
"Always" quiet at night	53%
"YES", patients would definitely recommend the hospital	83%
Staff "always" explained possible side effects	50%
Yes, staff "did" give patients information about possible symptoms	90%

Original Medicare doctor bills

$59,992

Medicare paid this office $59,992 for 395 people.

This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.

Sort by

Largest Original Medicare bills

Return visit (30+ min)	151	$20,478	$112
Testing of autonomic (sympathetic and parasympathetic) nervous system function, at least 5 minutes of tilt	70	$5,221	$75
Long return visit (40+ min)	29	$5,216	$149
New patient visit (60+ min)	29	$5,161	$178
Sleep study in sleep lab (6 years or older)	42	$4,511	$105

See all 14 services

Sort by

Every Original Medicare service billed

Return visit (30+ min)	151	$20,478	$112
Testing of autonomic (sympathetic and parasympathetic) nervous system function, at least 5 minutes of tilt	70	$5,221	$75
Long return visit (40+ min)	29	$5,216	$149
New patient visit (60+ min)	29	$5,161	$178
Sleep study in sleep lab (6 years or older)	42	$4,511	$105
Short return visit (20+ min)	41	$3,269	$80
New patient visit (45+ min)	20	$2,802	$140
Long return visit (40+ min)	15	$2,610	$130
Testing of autonomic (sympathetic) nervous system function	64	$2,472	$39
New patient visit (30+ min)	23	$2,107	$92
Sleep study in sleep lab	14	$957	$68
Sleep study including heart rate, breathing, and sleep time	24	$838	$35
Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's	29	$463	$15
Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's	13	$210	$15

Procedures Medicare counted

Sort by

Procedure volume Medicare published

Skin biopsy	1-10	None

Who their Medicare patients are

395 Original Medicare patients in 2024. Average age 70 · Under 65 16% · 85 and older 7% · Women 56% · Also on Medicaid 21% · Health risk score 1.34. At or below the middle of the specialty; the typical neuropsychiatry clinician is at 1.55.

Conditions among them: High blood pressure 61% · Depression 32% · Coronary heart disease 27% · Diabetes 23% · Chronic kidney disease 18% · Cancer 16% · Atrial fibrillation 16% · Heart failure 15% · Stroke 12% · COPD 11% · Dementia 9%.

The office billed $482,905, Medicare allowed $80,530 and paid $59,992; for 675 services of 21 kinds.

Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.

Year by year

Sort by

Original Medicare by year

2024	395	675	70	1.34	$482,905	$59,992
2023	340	614	70	1.25	$384,594	$48,959
2022	337	584	70	1.31	$365,412	$48,045
2021	337	553	70	1.43	$332,501	$45,999
2020	376	589	71	1.30	$305,968	$46,391
2019	404	597	71	1.39	$143,726	$49,249
2018	387	618	70	1.23	$141,333	$49,827
2017	431	719	70	1.39	$200,990	$59,279
2016	376	615	69	1.33	$197,557	$53,585
2015	344	556	69	1.31	$185,421	$50,656
2014	249	403	68	1.14	$129,303	$38,666
2013	99	121	66	1.22	$41,902	$13,435

Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.

See the services billed each year

2023: 13 services

Sort by

Original Medicare services billed in 2023

Return visit (30+ min)	114	$11,510	$81
Return visit (30+ min)	75	$8,383	$81
Testing of autonomic (sympathetic and parasympathetic) nervous system function, at least 5 minutes of tilt	64	$4,863	$76
Long return visit (40+ min)	32	$4,849	$131
Sleep study in sleep lab (6 years or older)	29	$3,104	$107
Long return visit (40+ min)	19	$2,766	$115
New patient visit (60+ min)	15	$2,338	$156
Testing of autonomic (sympathetic) nervous system function	55	$2,158	$39
Short return visit (20+ min)	24	$1,278	$51
Sleep study in sleep lab with continuous airway pressure (6 years or older)	11	$1,225	$111
Sleep study in sleep lab	12	$981	$75
New patient visit (30+ min)	11	$775	$70
Sleep study including heart rate, breathing, and sleep time	20	$734	$37

2022: 17 services

Sort by

Original Medicare services billed in 2022

Return visit (30+ min)	102	$9,424	$79
Return visit (30+ min)	65	$7,865	$80
Long return visit (40+ min)	42	$6,152	$118
New patient visit (60+ min)	30	$4,559	$152
Long return visit (40+ min)	29	$3,466	$116
Testing of autonomic (sympathetic and parasympathetic) nervous system function, at least 5 minutes of tilt	38	$3,059	$81
Sleep study in sleep lab with continuous airway pressure (6 years or older)	17	$1,893	$111
Testing of autonomic (sympathetic) nervous system function	34	$1,423	$42
New patient visit (45+ min)	11	$1,362	$124
Short return visit (20+ min)	20	$1,201	$57
Sleep study in sleep lab	14	$1,124	$80
Sleep study in sleep lab (6 years or older)	11	$1,112	$101
New patient visit (45+ min)	12	$941	$78
New patient visit (30+ min)	14	$700	$50
Sleep study including heart rate, breathing, and sleep time	14	$521	$37
Online digital evaluation and management service for an established patient for up to 7 days, total time 11-20 minutes	14	$379	$24
Online digital evaluation and management service for an established patient for up to 7 days, total time 11-20 minutes	14	$278	$17

2021: 11 services

Sort by

Original Medicare services billed in 2021

Return visit (30+ min)	108	$10,544	$80
Return visit (30+ min)	72	$7,592	$83
Long return visit (40+ min)	36	$5,554	$132
New patient visit (60+ min)	38	$5,482	$144
Testing of autonomic (sympathetic and parasympathetic) nervous system function, at least 5 minutes of tilt	45	$3,601	$80
Long return visit (40+ min)	19	$2,551	$121
Sleep study in sleep lab (6 years or older)	17	$1,878	$110
Testing of autonomic (sympathetic) nervous system function	41	$1,709	$42
New patient visit (30+ min)	15	$1,059	$71
Short return visit (20+ min)	14	$855	$61
Online digital evaluation and management service for an established patient for up to 7 days, total time 11-20 minutes	14	$313	$21

2020: 13 services

Sort by

Original Medicare services billed in 2020

Return visit (30+ min)	123	$9,949	$67
New patient visit (60+ min)	57	$7,911	$139
Return visit (30+ min)	80	$7,145	$69
Long return visit (40+ min)	41	$4,430	$94
Long return visit (40+ min)	33	$4,008	$100
Sleep study in sleep lab (6 years or older)	20	$1,966	$98
New patient visit (45+ min)	19	$1,927	$101
New patient visit (60+ min)	11	$1,749	$159
New patient visit (45+ min)	13	$1,186	$91
New patient visit (30+ min)	14	$902	$64
Testing of autonomic (sympathetic and parasympathetic) nervous system function, at least 5 minutes of tilt	11	$792	$72
Short return visit (20+ min)	12	$611	$47
Testing of autonomic (sympathetic) nervous system function	11	$349	$32

2019: 12 services

Sort by

Original Medicare services billed in 2019

Return visit (30+ min)	124	$10,993	$66
New patient visit (60+ min)	56	$8,087	$144
Return visit (30+ min)	85	$7,133	$67
Sleep study in sleep lab (6 years or older)	40	$4,257	$106
Long return visit (40+ min)	39	$4,139	$99
New patient visit (45+ min)	32	$3,573	$112
Sleep study in sleep lab with continuous airway pressure (6 years or older)	26	$2,634	$101
Testing of autonomic (sympathetic and parasympathetic) nervous system function, at least 5 minutes of tilt	22	$1,666	$76
Long return visit (40+ min)	13	$1,439	$96
New patient visit (45+ min)	12	$1,244	$104
Testing of autonomic (sympathetic) nervous system function	21	$827	$39
Short return visit (20+ min)	11	$459	$38

2018: 12 services

Sort by

Original Medicare services billed in 2018

Return visit (30+ min)	169	$14,107	$63
New patient visit (60+ min)	53	$6,944	$131
Long return visit (40+ min)	68	$6,451	$91
New patient visit (45+ min)	37	$3,869	$105
Sleep study in sleep lab with continuous airway pressure (6 years or older)	33	$3,552	$108
Sleep study in sleep lab (6 years or older)	30	$3,269	$109
Testing of autonomic (sympathetic and parasympathetic) nervous system function, at least 5 minutes of tilt	25	$1,940	$78
New patient visit (45+ min)	13	$1,499	$115
Return visit (30+ min)	18	$1,272	$71
Testing of autonomic (sympathetic) nervous system function	22	$878	$40
Short return visit (20+ min)	18	$779	$41
New patient visit (30+ min)	12	$741	$62

2017: 10 services

Sort by

Original Medicare services billed in 2017

Return visit (30+ min)	220	$18,938	$63
New patient visit (60+ min)	102	$14,016	$137
Long return visit (40+ min)	88	$9,806	$92
New patient visit (45+ min)	42	$4,408	$105
Testing of autonomic (sympathetic and parasympathetic) nervous system function, at least 5 minutes of tilt	41	$3,341	$81
Sleep study in sleep lab with continuous airway pressure (6 years or older)	24	$2,954	$114
Sleep study in sleep lab (6 years or older)	24	$2,276	$95
Testing of autonomic (sympathetic) nervous system function	39	$1,628	$42
Sleep study including heart rate, breathing, airflow, and effort	11	$607	$55
Short return visit (20+ min)	15	$546	$34

2016: 8 services

Sort by

Original Medicare services billed in 2016

New patient visit (60+ min)	116	$16,155	$139
Return visit (30+ min)	161	$14,079	$65
Long return visit (40+ min)	80	$7,993	$91
New patient visit (45+ min)	35	$3,808	$109
Testing of autonomic (sympathetic and parasympathetic) nervous system function, at least 5 minutes of tilt	43	$3,385	$79
Sleep study in sleep lab (6 years or older)	32	$3,220	$101
Testing of autonomic (sympathetic) nervous system function	18	$753	$42
Short return visit (20+ min)	14	$638	$46

2015: 8 services

Sort by

Original Medicare services billed in 2015

New patient visit (60+ min)	122	$16,931	$139
Return visit (30+ min)	141	$13,069	$66
Long return visit (40+ min)	84	$9,341	$93
Sleep study in sleep lab (6 years or older)	33	$3,368	$102
Testing of autonomic (sympathetic and parasympathetic) nervous system function, at least 5 minutes of tilt	24	$1,896	$79
Extended office or other outpatient service, first hour	18	$1,492	$83
Sleep study in sleep lab with continuous airway pressure (6 years or older)	13	$1,482	$114
New patient visit (45+ min)	12	$1,388	$116

2014: 5 services

Sort by

Original Medicare services billed in 2014

New patient visit (60+ min)	103	$14,250	$138
Long return visit (40+ min)	93	$11,207	$90
Return visit (30+ min)	90	$7,752	$69
Sleep study in sleep lab (6 years or older)	14	$1,537	$110
Testing of autonomic (sympathetic and parasympathetic) nervous system function, at least 5 minutes of tilt	12	$956	$80

2013: 2 services

Sort by

Original Medicare services billed in 2013

New patient visit (60+ min)	58	$8,393	$145
Long return visit (40+ min)	30	$3,052	$92

Medicaid work

$406 in 2023

Medicaid paid $406 for 13 billed services this clinician did in 2023, up to 13 people in a month for one service.

Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.

Sort by

Largest Medicaid services in 2023

Return visit (30+ min)	13	$406

Sort by

Medicaid work by year

2023	13	1	13	$406
2020	12	1	12	$284
2019	52	1	16	$1,891
2018	12	1	12	$358

See the largest Medicaid services in earlier years

2020

Sort by

Largest Medicaid services in 2020

Return visit (30+ min)	12	$284

2019

Sort by

Largest Medicaid services in 2019

Return visit (30+ min)	52	$1,891

2018

Sort by

Largest Medicaid services in 2018

Return visit (30+ min)	12	$358

Drugs they prescribed that Part D paid

$845,027

Pharmacies billed $845,027 in 2024.

This is pharmacy cost, not the office bill, and not what patients paid.

Opioids were 6% of their Part D prescriptions (63 of 1,111) in 2024. A higher opioid share than 9 in 10 peers; the typical neuropsychiatry clinician is at 0%. Long-acting opioids: 40% of their opioid prescriptions.

977 generic and 134 brand-name prescriptions · $845,027 in drug cost.

Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.

Sort by

Largest Part D drug costs

Xywav	None	22	$263,877	$11,994
Sodium Oxybate	None	12	$223,329	$18,611
Droxidopa	None	83	$169,359	$2,040
Gamunex-C	Immune globulin	22	$68,123	$3,096
Belsomra	None	35	$18,142	$518

See all 27 drugs

Sort by

Every Part D drug this clinician prescribed

Xywav	None	22	$263,877	$11,994
Sodium Oxybate	None	12	$223,329	$18,611
Droxidopa	None	83	$169,359	$2,040
Gamunex-C	Immune globulin	22	$68,123	$3,096
Belsomra	None	35	$18,142	$518
Neupro	None	18	$16,169	$898
Midodrine	None	80	$7,655	$96
Cromolyn	None	20	$5,342	$267
Modafinil	None	70	$2,845	$41
Pyridostigmine	None	45	$2,742	$61
Gabapentin	None	114	$1,846	$16
Carbidopa-Levodopa	None	23	$1,475	$64
Atomoxetine	None	23	$1,218	$53
Fludrocortisone Acetate	None	39	$977	$25
Carbamazepine	None	26	$802	$31
Pramipexole Dihydrochloride	None	36	$576	$16
Hydrocodone-Acetaminophen	None	18	$544	$30
Clonazepam	None	61	$452	$7
Methadone	None	25	$353	$14
Dextroamphetamine-Amphetamine	None	21	$349	$17
Propranolol	None	25	$287	$11
Donepezil	None	17	$274	$16
Prazosin	None	14	$238	$17
Eszopiclone	None	12	$204	$17
Nortriptyline	None	11	$144	$13
Zolpidem	None	11	$95	$9
Tramadol	None	20	$59	$3

Year by year

Sort by

Part D prescribing by year

2024	1,111	146	6% (63)	12%	$845,027
2023	817	144	7% (57)	None	$566,217
2022	828	136	6% (52)	7%	$404,377
2021	584	116	4% (21)	11%	$271,219
2020	640	124	2% (13)	10%	$314,992
2019	627	122	4% (24)	7%	$205,356
2018	841	143	5% (42)	12%	$375,054
2017	854	170	2% (13)	12%	$627,398
2016	759	131	3% (23)	17%	$575,703
2015	602	125	2% (12)	15%	$202,102
2014	344	77	None	10%	$22,322
2013	82	37	0% (0)	18%	$19,374

Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.

See the drugs prescribed each year

2023: 24 drugs

Sort by

Part D drugs prescribed in 2023

Droxidopa	63	$184,747	$2,932
Xywav	12	$110,651	$9,221
Neupro	12	$15,999	$1,333
Midodrine	78	$11,551	$148
Belsomra	26	$11,545	$444
Rivastigmine	12	$6,131	$511
Gabapentin	93	$2,573	$28
Carbidopa-Levodopa	33	$1,940	$59
Estazolam	12	$1,710	$142
Fludrocortisone Acetate	39	$1,441	$37
Nortriptyline	23	$838	$36
Eszopiclone	21	$823	$39
Modafinil	31	$813	$26
Pramipexole Dihydrochloride	15	$801	$53
Carbamazepine	14	$754	$54
Clonazepam	47	$661	$14
Pyridostigmine	15	$561	$37
Propranolol	16	$389	$24
Dextroamphetamine-Amphetamine	11	$340	$31
Methadone	21	$225	$11
Tramadol	25	$156	$6
Hydrocodone-Acetaminophen	11	$130	$12
Donepezil	13	$119	$9
Clonidine	13	$83	$6

2022: 23 drugs

Sort by

Part D drugs prescribed in 2022

Xyrem	12	$241,834	$20,153
Droxidopa	43	$78,698	$1,830
Modafinil	40	$13,893	$347
Belsomra	26	$12,836	$494
Cromolyn	15	$9,461	$631
Midodrine	82	$8,438	$103
Gabapentin	147	$3,313	$23
Estazolam	12	$1,710	$142
Levetiracetam	22	$1,110	$50
Nortriptyline	21	$874	$42
Pyridostigmine	14	$671	$48
Carbamazepine	12	$668	$56
Pramipexole Dihydrochloride	22	$656	$30
Fludrocortisone Acetate	24	$611	$25
Dextroamphetamine-Amphetamine	18	$529	$29
Clonazepam	50	$480	$10
Propranolol	14	$413	$30
Eszopiclone	11	$220	$20
Methadone	15	$182	$12
Tramadol	25	$150	$6
Hydrocodone-Acetaminophen	12	$141	$12
Clonidine	12	$48	$4
Trazodone	14	$34	$2

2021: 16 drugs

Sort by

Part D drugs prescribed in 2021

Xyrem	11	$205,839	$18,713
Neupro	24	$17,121	$713
Modafinil	35	$14,277	$408
Belsomra	24	$10,750	$448
Midodrine	67	$5,298	$79
Gabapentin	106	$1,430	$13
Pyridostigmine	22	$1,184	$54
Nortriptyline	32	$895	$28
Levetiracetam	27	$577	$21
Dextroamphetamine-Amphetamine	16	$536	$34
Fludrocortisone Acetate	20	$484	$24
Carbamazepine	12	$460	$38
Carbidopa-Levodopa	12	$201	$17
Trazodone	21	$122	$6
Methadone	12	$114	$10
Clonazepam	21	$70	$3

2020: 17 drugs

Sort by

Part D drugs prescribed in 2020

Xyrem	12	$206,960	$17,247
Neupro	16	$11,480	$717
Modafinil	52	$10,873	$209
Belsomra	17	$9,550	$562
Cromolyn	11	$7,030	$639
Midodrine	48	$4,908	$102
Nortriptyline	67	$1,488	$22
Gabapentin	120	$1,485	$12
Pyridostigmine	13	$576	$44
Dextroamphetamine-Amphetamine	12	$570	$48
Levetiracetam	26	$523	$20
Carbamazepine	11	$424	$39
Carbidopa-Levodopa	20	$403	$20
Clonazepam	16	$305	$19
Ondansetron	14	$206	$15
Trazodone	19	$145	$8
Zolpidem	15	$91	$6

2019: 10 drugs

Sort by

Part D drugs prescribed in 2019

Midodrine	38	$3,282	$86
Gabapentin	136	$2,988	$22
Modafinil	42	$2,608	$62
Nortriptyline	64	$1,791	$28
Levetiracetam	36	$836	$23
Propranolol	14	$354	$25
Donepezil	16	$223	$14
Ropinirole	16	$170	$11
Trazodone	19	$139	$7
Clonazepam	14	$57	$4

2018: 23 drugs

Sort by

Part D drugs prescribed in 2018

Northera	29	$327,757	$11,302
Neupro	19	$12,366	$651
Modafinil	37	$8,500	$230
Belsomra	13	$4,321	$332
Gabapentin	168	$3,393	$20
Midodrine	41	$2,729	$67
Dextroamphetamine-Amphet Er	12	$2,126	$177
Nortriptyline	85	$1,694	$20
Memantine	29	$1,470	$51
Fludrocortisone Acetate	39	$627	$16
Levetiracetam	20	$531	$27
Donepezil	13	$438	$34
Prazosin	19	$416	$22
Carbidopa-Levodopa	12	$318	$26
Methadone	20	$276	$14
Clonidine	28	$204	$7
Captopril	13	$162	$12
Hydrocodone-Acetaminophen	11	$142	$13
Pramipexole Dihydrochloride	11	$119	$11
Zolpidem	18	$107	$6
Escitalopram	18	$93	$5
Clonazepam	23	$79	$3
Ondansetron	16	$79	$5

2017: 20 drugs

Sort by

Part D drugs prescribed in 2017

Northera	52	$529,373	$10,180
Neupro	12	$7,552	$629
Midodrine	83	$6,242	$75
Modafinil	18	$5,678	$315
Gabapentin	190	$2,492	$13
Carbidopa-Levodopa	27	$897	$33
Fludrocortisone Acetate	57	$834	$15
Nortriptyline	44	$828	$19
Pyridostigmine	13	$572	$44
Levetiracetam	20	$543	$27
Amitriptyline	11	$338	$31
Captopril	15	$317	$21
Propranolol	21	$237	$11
Verapamil	11	$217	$20
Pramipexole Dihydrochloride	15	$147	$10
Zolpidem	12	$63	$5
Hydralazine	11	$55	$5
Escitalopram	13	$53	$4
Clonazepam	14	$42	$3
Clonidine	23	$35	$2

2016: 15 drugs

Sort by

Part D drugs prescribed in 2016

Northera	74	$541,331	$7,315
Modafinil	20	$8,789	$439
Midodrine	75	$7,860	$105
Gabapentin	169	$2,233	$13
Pyridostigmine	15	$752	$50
Fludrocortisone Acetate	35	$721	$21
Propranolol	30	$550	$18
Carbidopa-Levodopa	28	$447	$16
Nortriptyline	38	$410	$11
Amitriptyline	15	$367	$24
Zolpidem	26	$249	$10
Metoprolol	14	$207	$15
Sumatriptan	12	$195	$16
Pramipexole Dihydrochloride	12	$152	$13
Clonidine	16	$24	$2

2015: 17 drugs

Sort by

Part D drugs prescribed in 2015

Northera	36	$168,079	$4,669
Modafinil	19	$12,479	$657
Midodrine	61	$4,611	$76
Gabapentin	108	$1,884	$17
Carbamazepine Er	12	$931	$78
Pyridostigmine	16	$819	$51
Fludrocortisone Acetate	31	$657	$21
Propranolol	41	$591	$14
Carbidopa-Levodopa	25	$505	$20
Levetiracetam	13	$500	$38
Propranolol Hcl Er	11	$437	$40
Rizatriptan	15	$387	$26
Topiramate	11	$327	$30
Nortriptyline	29	$313	$11
Metoprolol	12	$290	$24
Amitriptyline	16	$225	$14
Zolpidem	14	$75	$5

2014: 9 drugs

Sort by

Part D drugs prescribed in 2014

Midodrine	32	$1,562	$49
Gabapentin	57	$654	$11
Sumatriptan	21	$451	$21
Nortriptyline	33	$383	$12
Rizatriptan	15	$357	$24
Metoprolol	11	$169	$15
Propranolol	17	$149	$9
Topiramate	17	$126	$7
Baclofen	13	$121	$9

2013: 1 drug

Sort by

Part D drugs prescribed in 2013

Midodrine	13	$1,091	$84

Money from drug and device companies

$21,981 in 2025

Sort by

Industry payments by year

2025	3	30	$19,652	$21,981
2024	2	7	$5,360	$5,963
2023	4	29	$12,090	$14,603
2022	3	10	$7,960	$8,598
2019	1	1	None	$41

Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.

A payment is not proof that care is biased.

Sort by

Payments by company

Jazz Pharmaceuticals	Xywav	$18,646	27 payments Meals for Xywav · 2025-12-18 · $132 Consulting · 2025-11-17 · $741 Meals for Xywav · 2025-10-10 · $91 Consulting for Xywav · 2025-07-02 · $13,338 Meals for Xywav · 2025-07-02 · $134 Travel for Xywav · 2025-07-02 · $63 Meals for Xywav · 2025-07-02 · $62 Travel for Xywav · 2025-07-02 · $58 Travel for Xywav · 2025-07-02 · $48 Travel for Xywav · 2025-07-02 · $41 Travel for Xywav · 2025-07-02 · $20 Travel for Xywav · 2025-07-02 · $8 Travel for Xywav · 2025-07-02 · $8 Meals for Xywav · 2025-06-12 · $61 Meals for Xywav · 2025-06-11 · $135 Meals for Xyrem · 2025-06-09 · $150 Meals · 2025-06-09 · $104 Meals for Xywav · 2025-06-06 · $75 Meals for Xywav · 2025-06-06 · $50 Meals for Xywav · 2025-06-06 · $15 Meals for Xywav · 2025-06-06 · $15 Travel for Xywav · 2025-06-05 · $368 Travel for Xywav · 2025-06-05 · $341 Consulting for Xywav · 2025-05-30 · $2,223 Meals for Xywav · 2025-04-06 · $67 Meals for Xywav · 2025-02-20 · $150 Consulting for Xywav · 2025-01-16 · $150
Lundbeck	None	$3,200	1 payment Honoraria · 2025-12-23 · $3,200
Harmony Biosciences	Wakix	$135	2 payments Meals for Wakix · 2025-06-10 · $44 Meals for Wakix · 2025-04-05 · $91

See all 30 published payments

Sort by

Every published payment

Lundbeck	Honoraria · 2025-12-23	None	$3,200
Jazz Pharmaceuticals	Meals · 2025-12-18	Xywav	$132
Jazz Pharmaceuticals	Consulting · 2025-11-17	None	$741
Jazz Pharmaceuticals	Meals · 2025-10-10	Xywav	$91
Jazz Pharmaceuticals	Consulting · 2025-07-02	Xywav	$13,338
Jazz Pharmaceuticals	Meals · 2025-07-02	Xywav	$134
Jazz Pharmaceuticals	Travel · 2025-07-02	Xywav	$63
Jazz Pharmaceuticals	Meals · 2025-07-02	Xywav	$62
Jazz Pharmaceuticals	Travel · 2025-07-02	Xywav	$58
Jazz Pharmaceuticals	Travel · 2025-07-02	Xywav	$48
Jazz Pharmaceuticals	Travel · 2025-07-02	Xywav	$41
Jazz Pharmaceuticals	Travel · 2025-07-02	Xywav	$20
Jazz Pharmaceuticals	Travel · 2025-07-02	Xywav	$8
Jazz Pharmaceuticals	Travel · 2025-07-02	Xywav	$8
Jazz Pharmaceuticals	Meals · 2025-06-12	Xywav	$61
Jazz Pharmaceuticals	Meals · 2025-06-11	Xywav	$135
Harmony Biosciences	Meals · 2025-06-10	Wakix	$44
Jazz Pharmaceuticals	Meals · 2025-06-09	Xyrem	$150
Jazz Pharmaceuticals	Meals · 2025-06-09	None	$104
Jazz Pharmaceuticals	Meals · 2025-06-06	Xywav	$75
Jazz Pharmaceuticals	Meals · 2025-06-06	Xywav	$50
Jazz Pharmaceuticals	Meals · 2025-06-06	Xywav	$15
Jazz Pharmaceuticals	Meals · 2025-06-06	Xywav	$15
Jazz Pharmaceuticals	Travel · 2025-06-05	Xywav	$368
Jazz Pharmaceuticals	Travel · 2025-06-05	Xywav	$341
Jazz Pharmaceuticals	Consulting · 2025-05-30	Xywav	$2,223
Jazz Pharmaceuticals	Meals · 2025-04-06	Xywav	$67
Harmony Biosciences	Meals · 2025-04-05	Wakix	$91
Jazz Pharmaceuticals	Meals · 2025-02-20	Xywav	$150
Jazz Pharmaceuticals	Consulting · 2025-01-16	Xywav	$150

See earlier years (2024, 2023, 2022, 2019)

2024: $5,963

Sort by

Payments by company in 2024

Jazz Pharmaceuticals	Xywav	$5,915	6 payments Consulting for Xywav · 2024-09-18 · $2,680 Consulting · 2024-09-17 · $2,680 Meals · 2024-08-21 · $122 Meals for Xywav · 2024-08-20 · $150 Meals for Xywav · 2024-04-25 · $142 Meals for Xywav · 2024-02-08 · $140
Harmony Biosciences	Wakix	$48	1 payment Meals for Wakix · 2024-02-16 · $48

2023: $14,603

Sort by

Payments by company in 2023

Jazz Pharmaceuticals	Xywav	$13,774	15 payments Meals for Xywav · 2023-12-13 · $140 Meals for Xywav · 2023-09-20 · $146 Meals for Xywav · 2023-09-11 · $29 Travel for Xywav · 2023-09-11 · $105 Paid to speak or teach for Xywav · 2023-09-05 · $9,240 Travel for Xywav · 2023-08-25 · $32 Meals for Xywav · 2023-08-25 · $24 Meals for Xywav · 2023-08-25 · $11 Meals for Xywav · 2023-08-25 · $50 Meals for Xywav · 2023-08-25 · $75 Travel for Xywav · 2023-08-24 · $348 Travel for Xywav · 2023-08-24 · $428 Meals for Xywav · 2023-07-18 · $145 Meals for Xywav · 2023-04-19 · $150 Consulting for Xywav · 2023-03-03 · $2,850
Argenx US	Vyvgart	$696	12 payments Meals for Vyvgart · 2023-02-01 · $59 Meals for Vyvgart · 2023-02-01 · $24 Meals for Vyvgart · 2023-02-01 · $123 Meals for Vyvgart · 2023-02-01 · $50 Meals for Vyvgart · 2023-02-01 · $50 Travel for Vyvgart · 2023-02-01 · $225 Travel for Vyvgart · 2023-02-01 · $53 Meals for Vyvgart · 2023-02-01 · $24 Meals for Vyvgart · 2023-02-01 · $19 Meals for Vyvgart · 2023-01-31 · $6 Meals for Vyvgart · 2023-01-31 · $25 Travel for Vyvgart · 2023-01-31 · $37
Harmony Biosciences	Wakix	$92	1 payment Meals for Wakix · 2023-04-12 · $92
Alnylam Pharmaceuticals	Amvuttra	$41	1 payment Meals for Amvuttra · 2023-11-16 · $41

2022: $8,598

Sort by

Payments by company in 2022

Jazz Pharmaceuticals	Sunosi	$7,968	8 payments Consulting for Xywav · 2022-12-19 · $2,850 Meals · 2022-11-09 · $150 Consulting for Sunosi · 2022-09-27 · $2,280 Meals · 2022-09-22 · $114 Consulting for Sunosi · 2022-07-21 · $2,280 Meals for Xywav · 2022-05-17 · $144 Meals for Xywav · 2022-03-30 · $41 Meals for Xywav · 2022-03-30 · $109
Pfizer	None	$550	1 payment Consulting · 2022-08-05 · $550
Harmony Biosciences	Wakix	$81	1 payment Meals for Wakix · 2022-05-04 · $81

2019: $41

Sort by

Payments by company in 2019

Jazz Pharmaceuticals	Xyrem	$41	1 payment Meals for Xyrem · 2019-06-10 · $41

Research money

Money a company paid to run a study. Where it went to their institution, the clinician is named as an investigator and did not receive it; the amount covers the whole study, often across many sites.

Sort by

Research payments by company and study

ARGENX US, INC. · Quincy Model - A Phase 2 Randomized, Double-Blinded, Placebo-Controlled Study To Evaluate the Efficacy and Safety of Efgartigimod IV in Adult Patients With Postcovid-19 Postural Orthostatic Tachycardia Syndrome (Pots) · 2024	Their institution	$183,718
ARGENX US, INC. · A Phase 3, Multicenter, Randomized, Double-Blinded, Placebo-Controlled Trial To Evaluate the Efficacy and the Safety of Efgartigimod (Argx-113) Ph20 Subcutaneous in Adult Patients With Primary Immune Thrombocytopenia · 2023	Their institution	$134,415
ARGENX US, INC. · Quincy Model - Open-Label Extension Study To Evaluate the Long Term Safety and Efficacy of Efgartigimod in Adult Patients With Post-Covid-19 Postural Orthostatic Tachycardia Syndrome (PC-Pots) Who Completed Study Argx 113-2104 · 2024	Their institution	$125,382
Regeneron Pharmaceuticals, Inc. · A Phase 2 Double-Blind Placebo-Controlled Single-Dose Study of Pharmacodynamics, Pharmacokinetics, Safety, and Tolerability of Regn7544, An Npr1 Antagonist Monoclonal Antibody, in Patients With Postural Orthostatic Tachycardia Syndrome · 2025	Their institution	$117,910
ARGENX US, INC. · Efficacy and Safety Study of Efgartigimod in Adults With Post-Covid-19 Pots · 2023	Their institution	$72,297
ARGENX US, INC. · A Phase 3, Multicenter, Randomized, Double-Blinded, Placebo-Controlled Trial To Evaluate the Efficacy and the Safety of Efgartigimod (Argx-113) Ph20 Subcutaneous in Adult Patients With Primary Immune Thrombocytopenia · 2024	Their institution	$37,007
Biohaven Pharmaceuticals, Inc. · A Randomized, Double-Blind, Placebo-Controlled, Parallel- Group Study To Evaluate the Efficacy and Safety of Bhv-3241 in Subjects With Multiple System Atrophy (M-Star Study) · 2021	Their institution	$33,288
ARGENX US, INC. · Open-Label Extension Study To Evaluate the Long-Term Safety and Efficacy of Efgartigimod in Adult Patients With Post-Covid-19 Postural Orthostatic Tachycardia Syndrome (PC-Pots) Who Completed Study Argx-113-2104 · 2023	Their institution	$29,863
Biohaven Pharmaceutical Holding Company Ltd. · A Randomized Double-Blind Placebo-Controlled Parallel- Group Study To Evaluate the Efficacy and Safety of Bhv-3241 in Subjects With Multiple System Atrophy (M-Star Study) · 2022	Their institution	$22,432
ARGENX US, INC. · Quincy Model - Open-Label Extension Study To Evaluate the Long Term Safety and Efficacy of Efgartigimod in Adult Patients With Post-Covid-19 Postural Orthostatic Tachycardia Syndrome (PC-Pots) Who Completed Study Argx 113-2104 · 2025	Their institution	$14,622
Biohaven Pharmaceuticals, Inc. · A Randomized, Double-Blind, Placebo-Controlled, Parallel- Group Study To Evaluate the Efficacy and Safety of Bhv-3241 in Subjects With Multiple System Atrophy (M-Star Study) · 2020	Their institution	$2,212
ARGENX US, INC. · A Phase 3, Multicenter, Randomized, Double-Blinded, Placebo-Controlled Trial To Evaluate the Efficacy and the Safety of Efgartigimod (Argx-113) Ph20 Subcutaneous in Adult Patients With Primary Immune Thrombocytopenia · 2022	Their institution	$1,421

Checkups this office reported

Medicare did not publish checkup rates for this clinician.

Medicare’s overall office score: 76.5 / 100; Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.

Professional record

NPI: 1972779411
Licence: CA A121294California A121294: Current · expires 2028-03-31
Trained: University of Florida College of Medicine, 2007
Group: Stanford Health Care
Video visits: Lists video visits
Gender: Male

More record details

Sole proprietor: No
Taxonomy: Federal specialty code 2084N0600X (2084N0600X); Neurology (2084N0400X); Federal specialty code 2084S0012X (2084S0012X)
Mailing address: 300 Pasteur Dr, Stanford, CA, 94305
NPI first listed: 2008-05-05
NPI last updated: 2023-11-10
NPI record certified: 2023-11-10

This is when the NPI record was last certified, not a medical board exam.

Extra NPI addresses: 450 Broadway St, Redwood City, CA, 94063